论文部分内容阅读
目的观察重组人生长激素(rhGH)治疗肝炎后肝硬化低蛋白血症的临床疗效。方法治疗组35例,用rhGH4U/d;对照组30例,用人血清清蛋白20～30g/周,2周为1个疗程,共治疗2个疗程。治疗前后分别测定肝功能、血清清蛋白,并观察临床症状变化。结果治疗组临床症状明显减轻,血清ALT、AST和总胆红素(TBil)水平降低,血清清蛋白水平提高,PT明显缩短(P<005或P<001),在改善血清清蛋白水平和PT方面明显优于对照组(P<005),未见明显不良反应。结论rhGH可以克服肝硬化患者的生长激素抵抗现象,明显提高患者肝脏合成清蛋白能力和改善临床症状,临床应用安全。
Objective To observe the clinical efficacy of recombinant human growth hormone (rhGH) in the treatment of posthepatitic cirrhosis and hypoproteinemia. Methods 35 cases of treatment group, with rhGH4U / d; control group of 30 patients with human serum albumin 20 ~ 30g / week, 2 weeks for a course of treatment, a total of 2 courses of treatment. Before and after treatment were measured liver function, serum albumin, and observed changes in clinical symptoms. Results The clinical symptoms of the treatment group were significantly reduced, serum ALT, AST and total bilirubin (TBil) levels were decreased, serum albumin level was increased, PT was significantly shortened (P <005 or P <001), the serum albumin level and PT Obviously superior to the control group (P <005), no obvious adverse reactions. Conclusion rhGH can overcome the growth hormone resistance in patients with liver cirrhosis, significantly improve liver capacity of patients with synthetic albumin and improve clinical symptoms, clinical application of safety.